Company: RGNT
Filing Date: 2025-03-11
Form Type: F-1
Source: 0001213900-25-022350
Chunk: 20

Company: REGENTIS BIOMATERIALS LTD.
Filing Date: 2025-03-11
Form: F-1
Chunk 20
---
 favorable terms                                                                                                            
 in any collaboration, licensing or other arrangements into which we may enter and perform our obligations under such collaborations; |

| ● | maintain, protect and expand                                                                                       
 our portfolio of intellectual property rights, including patents, patent applications, trade secrets and know-how; |

| ● | avoid and defend against                             
 third-party interference or infringement claims; and |

| ● | attract, hire and retain 
 qualified personnel.     |

We
anticipate incurring significant incremental costs associated with commercializing such product candidates. Our expenses could increase
beyond expectations if we are required by the FDA, or other regulatory agencies, domestic or foreign, to change our manufacturing processes
or assays or to perform studies in addition to those that we currently anticipate. Even if we are successful in obtaining additional
regulatory approvals to market our GelrinC or any future product candidates, our revenue earned from such product candidates will be
dependent in part upon the size of the markets in the territories for which we gain regulatory approval for such products, the accepted
price for such products, our ability to obtain reimbursement for such products at any price, whether we own the commercial rights for
that territory in which such products have been approved and the expenses associated with manufacturing and marketing such products for
such markets. Therefore, we may not generate significant revenue from the sale of such products. Further, if we are not able to generate
significant revenue from the sale of our approved products, we may be forced to curtail or cease our operations. Due to the numerous
risks and uncertainties involved in product development, it is difficult to predict the timing or amount of increased expenses, or when,
or if, we will be able to achieve or maintain profitability.

Even if this offering is successful, we will need to raise substantial additional funding, which may not be available on acceptable terms, or at all. Failure to obtain funding on acceptable terms and on a timely basis may require us to curtail, delay or discontinue our product development efforts or other operations.

As of June 30, 2024 and December
31, 2023, our cash and cash equivalents were approximately $0.2 million and $0.3 million, respectively, and we had a negative working
capital of approximately $0.9 million and $2.8 million, respectively, and an accumulated deficit of approximately $39.7 million and $46.9
million, respectively. Based on our current plans, we believe that our existing cash, cash equivalents and short-term deposits